Analysts Set Phreesia, Inc. (NYSE:PHR) Price Target at $29.42

Shares of Phreesia, Inc. (NYSE:PHR) have received a consensus recommendation of “Moderate Buy” from the twelve brokerages that are currently covering the stock, MarketBeat.com reports. One research analyst has rated the stock with a hold rating and eleven have given a buy rating to the company. The average 1 year price objective among brokerages that have issued a report on the stock in the last year is $29.42.

PHR has been the subject of several research analyst reports. Needham & Company LLC restated a “buy” rating and issued a $29.00 price objective on shares of Phreesia in a report on Thursday, September 5th. Robert W. Baird raised their target price on shares of Phreesia from $31.00 to $34.00 and gave the company an “outperform” rating in a research note on Friday, September 6th. JPMorgan Chase & Co. raised their target price on shares of Phreesia from $27.00 to $28.00 and gave the company an “overweight” rating in a research note on Monday, September 9th. Canaccord Genuity Group reaffirmed a “buy” rating and set a $34.00 target price on shares of Phreesia in a research note on Thursday, September 5th. Finally, DA Davidson reaffirmed a “buy” rating and set a $32.00 target price on shares of Phreesia in a research note on Thursday, September 5th.

Phreesia Stock Performance

Phreesia stock opened at $18.46 on Friday. The company has a current ratio of 1.77, a quick ratio of 1.77 and a debt-to-equity ratio of 0.03. Phreesia has a 1-year low of $14.28 and a 1-year high of $29.16. The firm has a 50-day moving average of $22.04 and a 200-day moving average of $22.07. The firm has a market cap of $1.07 billion, a P/E ratio of -10.26 and a beta of 0.95.

Phreesia (NYSE:PHR) last issued its quarterly earnings data on Wednesday, September 4th. The company reported ($0.31) EPS for the quarter, topping the consensus estimate of ($0.37) by $0.06. Phreesia had a negative net margin of 25.73% and a negative return on equity of 39.34%. The business had revenue of $102.12 million during the quarter, compared to analyst estimates of $101.76 million. Sell-side analysts expect that Phreesia will post -1.23 EPS for the current year.

Insider Activity at Phreesia

In related news, General Counsel Allison C. Hoffman sold 14,110 shares of the firm’s stock in a transaction that occurred on Monday, August 26th. The shares were sold at an average price of $26.03, for a total transaction of $367,283.30. Following the completion of the sale, the general counsel now owns 121,003 shares of the company’s stock, valued at $3,149,708.09. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. In other Phreesia news, General Counsel Allison C. Hoffman sold 1,212 shares of the business’s stock in a transaction dated Tuesday, October 15th. The stock was sold at an average price of $21.03, for a total transaction of $25,488.36. Following the completion of the sale, the general counsel now directly owns 119,791 shares in the company, valued at $2,519,204.73. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, General Counsel Allison C. Hoffman sold 14,110 shares of the business’s stock in a transaction dated Monday, August 26th. The shares were sold at an average price of $26.03, for a total value of $367,283.30. Following the sale, the general counsel now owns 121,003 shares of the company’s stock, valued at approximately $3,149,708.09. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 44,107 shares of company stock valued at $1,035,226 over the last 90 days. Corporate insiders own 5.80% of the company’s stock.

Institutional Investors Weigh In On Phreesia

Large investors have recently made changes to their positions in the company. International Assets Investment Management LLC grew its stake in shares of Phreesia by 2,179.7% during the 3rd quarter. International Assets Investment Management LLC now owns 1,459 shares of the company’s stock valued at $33,000 after purchasing an additional 1,395 shares during the period. nVerses Capital LLC grew its stake in shares of Phreesia by 76.5% during the 2nd quarter. nVerses Capital LLC now owns 3,000 shares of the company’s stock valued at $64,000 after purchasing an additional 1,300 shares during the period. EntryPoint Capital LLC bought a new stake in shares of Phreesia during the 1st quarter valued at about $169,000. Quadrature Capital Ltd bought a new stake in shares of Phreesia during the 1st quarter valued at about $202,000. Finally, Lombard Odier Asset Management USA Corp bought a new stake in shares of Phreesia during the 2nd quarter valued at about $202,000. 92.10% of the stock is currently owned by institutional investors.

Phreesia Company Profile

Phreesia, Inc provides an integrated SaaS-based software and payment platform for the healthcare industry in the United States and Canada. The company offers access solutions that offers appointment scheduling system for online appointments, reminders, and referral tracking management; registration solution to automate patient self-registration; revenue cycle solution, which offer insurance-verification processes, point-of-sale payments applications, post-visit payment collection, and flexible payment options; and network connect solution to deliver clinically relevant content to patients.